Abstract 1686P
Background
As global cancer cases increase exponentially, the number of caregivers subsequently increases to support patients. Despite being indispensable, the available resource was reserved mainly for patients, undermining the importance of caregivers who also share the struggle and burden. The chronic amount of stress and responsibility that caregivers face leads to impairment of quality of life (QOL). Further, most research that assesses the QOL is mainly conducted in the developed countries with robust palliative care. This comparative study aims to map and explore the status quo of QOL levels from caregivers of cancer patients in Asia. In addition, to investigate the correlation of QOL impairments in caregivers with sociodemographic factors.
Methods
A comprehensive systematic review of the literature was performed through databases with the keywords “cancer”, “caregiver”,” quality of life”, and “Asia” spans from 2004-2024. 371 articles that satisfy eligible criteria were retrieved. A total of 1271 family caregivers for cancer patients who had taken outpatient treatment, finished sociodemographic, and the Caregiver Quality of Life Index-Cancer (CQOLC) survey were included. Gathered CQOLC total scores from 12 countries including Indonesia, Singapore, Malaysia, Turkey, Iran, Jordanian, India, South Korea, China, Taiwan, Japan, and Saudi Arabia dataset, were compared and analyzed for their correlation with sociodemographic factors.
Results
Different distributions of total scores of CQOLC in 12 Asia countries observed with higher CQOLC total scores were scored within the developed countries with mature palliative care systems. Further, varying caregiver determinants including different sociodemographic characteristics could produce impaired QOL such as male gender, parental relationships, certain ethnicity, and late-stage cancer.
Conclusions
Despite sharing cultural context and family-based caregivers, uneven QOL distribution was observed across Asian countries. This study also highlights the potential areas to be improved. Additionally, acknowledging the diversity of values, culture, and socio-demographics significantly helps in creating more optimal interventions to support caregivers.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1709P - Outcomes with novel combinations in non-clear cell renal cell carcinoma (nccRCC): ORACLE study
Presenter: Deepak Kilari
Session: Poster session 11
1710P - Exposure-response (E/R) relationship of nivolumab (N) and ipilimumab (I) in patients (pts) with metastatic renal cell clear cell carcinoma (mRCC) from the randomised phase II BIONIKK study
Presenter: Benoit Blanchet
Session: Poster session 11
1711P - Real-word data challenging the treatment paradigm in metastatic renal cancer: Time to separate IMDC intermediate / poor risk groups?
Presenter: John McGrane
Session: Poster session 11
1712P - Real-world efficacy of first-line nivolumab plus ipilimumab and its practical predictive biomarkers in advanced renal cell carcinoma: First analysis from RENOIR study [KCSG GU22-13]
Presenter: Jwa Hoon Kim
Session: Poster session 11
1713P - A deep learning approach utilizing the electronic health record (EHR) to identify cancer recurrence in renal cell carcinoma (RCC)
Presenter: Jue Hou
Session: Poster session 11
1714P - Detection and monitoring of translocation renal cell carcinoma via epigenomic profiling of cell-free DNA
Presenter: Simon Garinet
Session: Poster session 11
1715P - Interim analysis results from a phase II study of adjuvant penpulimab in very high-risk clear cell renal cell carcinoma
Presenter: Xu Zhang
Session: Poster session 11
1716P - Primary resistance to front-line immune-based combinations in patients with advanced renal cell carcinoma (ARON-1)
Presenter: martina catalano
Session: Poster session 11